WO2007072923A1 - ステロイドの経時的安定性が改善された外用製剤 - Google Patents
ステロイドの経時的安定性が改善された外用製剤 Download PDFInfo
- Publication number
- WO2007072923A1 WO2007072923A1 PCT/JP2006/325541 JP2006325541W WO2007072923A1 WO 2007072923 A1 WO2007072923 A1 WO 2007072923A1 JP 2006325541 W JP2006325541 W JP 2006325541W WO 2007072923 A1 WO2007072923 A1 WO 2007072923A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- steroid
- external preparation
- present
- preparation
- mass
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to an external preparation containing a steroid and having a good feeling of use with improved steroid stability over time. More specifically, the present invention relates to an external preparation containing a steroid and containing a benzoate-based local anesthetic and oxycarboxylic acid, thereby improving the steroid stability over time and improving the steroid stability over time.
- the base contains 0. 005-0. 05 weight 0/0 of the steroid, a NOP agent containing 15 weight 0/0 following Kurota mittens and a surfactant as a stabilizer, the amount of said crotamiton is blended amount of the steroid
- a steroid-containing cataplasm containing 200 to 3000 times the weight of the surfactant and 1/20 to 1/5 times the compounding amount of the crotamiton (Patent Document 3);
- An anhydrous external preparation composition (Patent Document 4) containing an amount of an acrylic acid polymer effective for an inflammatory drug and its stability is known.
- anhydrous external preparation thread and product may not have a feeling of use because, for example, it does not contain moisture, and the formulation does not spread well.
- Patent Document 1 JP 2002-356430 A
- Patent Document 2 JP 2001-247463 A
- Patent Document 3 Japanese Patent Laid-Open No. 2000-26299
- Patent Document 4 Japanese Patent Laid-Open No. 2001-233772
- An object of the present invention is to provide an external preparation containing a steroid, wherein the stability over time of the steroid is improved and the usability is good.
- the present invention is as follows.
- Oxycarboxylic acid strength The preparation for external use according to any one of (1) to (4), which is citrate or malic acid.
- the steroid is not limited to those having an anti-inflammatory action (adrenocortical steroid), and can be incorporated into an external preparation as long as it can be stabilized by a benzoate local anesthetic and oxycarboxylic acid.
- All steroids are included, but in the present invention, corticosteroids are preferred. Specific examples of such steroids include hydrocortisone, amsinodo, predo-zolone, methylpredo-zolone, diflucortron, dexamethasone, betamethasone, diflorazone, difluprednate, triamcinolone, triamcino lonacetodo, harcinodo.
- ester steroids that form esters with organic acids, specifically, dexamethasone acetate, prednisolone acetate, hydrocortisone acetate, betamethasone valerate, prednisolone acetate valerate and the like are preferred.
- Dexamethasone acetate is particularly preferred.
- steroids may be used alone or in combination of two or more.
- the external preparation of the present invention has an advantageous effect when the stability over time is sufficiently improved even for steroids, especially when hydrolysis occurs and the stability of V is low, and ester-based steroids are sufficiently stable over time. Have.
- the compounding amount of the steroid in the total amount of the external preparation is not particularly limited, but is usually 0.001 to 1% by mass, preferably 0.005 to 0.5% by mass, and particularly preferably 0.01- 0.5% by mass is desirable from the viewpoint of pharmacological effects and safety of steroids.
- the benzoate-based local anesthetic in the present invention is a known component having an anesthetic action. To date, the improvement of steroid stability over time in an external preparation as in the present invention has been known. It is not done.
- benzoic acid ester system Specific examples of local anesthetics include, but are not limited to, lidocaine, lidocaine hydrochloride, dibu force hydrochloride, procaine hydrochloride, and the like. Even components that are not currently known can be used as long as they can stabilize steroids with oxycarboxylic acids. In the present invention, lidocaine is particularly preferable. In the present invention
- Benzoate-based local anesthetics may be used alone or in combination of two or more.
- the blending amount of the benzoate local anesthetic in the total amount of the external preparation is not particularly limited, but is usually 0.01 to 4% by mass, preferably 0.05 to 2%. Mass. / 0 , particularly preferably 0.1 to 1% by mass, is also desirable from the viewpoint of steroid stabilization and anesthetic action.
- the term “oxycarboxylic acid” refers to an organic compound having a carboxyl group and a hydroxyl group in one molecule.
- the oxycarboxylic acid may be a pharmacologically acceptable salt thereof.
- the salt include sodium salt, potassium salt, calcium salt and the like.
- Specific examples of the oxycarboxylic acid include, but are not limited to, lactic acid, citrate, malic acid, and the like.
- cuenic acid or phosphonic acid is particularly preferred.
- the organic carboxylic acids may be used alone or in combination of two or more.
- the compounding amount of oxycarboxylic acid in the total amount of the external preparation is not particularly limited, but is usually 0.001 to 2% by mass, preferably 0.01 to 1% by mass, and particularly preferably. 0.1 to 0. be 5 mass 0/0, the viewpoint force of stability I spoon steroid also desirable.
- each benzoate ester Local anesthetic is preferably 0.01 to 4000, more preferably ⁇ 0.1 to 400, particularly preferably ⁇ or 0.2 to 100, talented norebon acid strength is preferably ⁇ or 0.00 1 to 2000, and more.
- the viewpoint power of the stability over time of the steroid is particularly preferable when it is preferably 0.02 to 200, particularly preferably 0.2 to 50.
- the dosage form of the external preparation is not particularly limited as long as the stability of the steroid is required, such as an external preparation containing water.
- examples include reaming agents, gels, ointments and patches.
- a liquid agent, a cream agent, or a gel agent is particularly preferable from the viewpoint of the feeling of use of the preparation.
- the stability of the steroid in the external preparation of the present invention is presumed mainly due to the inhibition of hydrolysis of steroids, particularly ester steroids. Therefore, in a preferred embodiment of the external preparation of the present invention, 0.1 to 99% by weight, preferably 5 to 95% by weight, particularly preferably 10 to 90% by weight of water is preferably used relative to the total amount of the external preparation. Including.
- the pH of the external preparation is usually 3 to 8, preferably 4 to 7.
- dexamethasone acetate may become unstable when the pH of an external preparation is lower than 3 or higher than the pH strength.
- a more preferable pH for dexamethasone acetate is 5 to 6.5.
- the external preparation has a pH lower than 3, or a pH higher than 8, it may irritate the skin.
- an antihistamine can be further added.
- the antihistamine is a known component having an antipruritic action, and an immediate antipruritic action can be obtained by combining with an external preparation in the present invention.
- Specific examples of the antihistamine include, but are not limited to, for example, diphenhydramine hydrochloride, diphenhydramine, chlorfelamine maleate, isotipezil hydrochloride, and the like. These may be used alone or in combination of two or more. In the present invention, diphenhydramine and diphenhydramine hydrochloride are particularly preferable.
- the compounding amount of the antihistamine in the total amount of the external preparation is not particularly limited, but is usually 0.1 to 4% by mass, preferably 0.5 to 3% by mass, particularly Preferably, the amount of 0.75 to 2% by mass is also desirable from the viewpoint of antipruritic action.
- the external preparation of the present invention may further contain a lower alcohol.
- a lower alcohol By blending a lower alcohol in the present invention, the skin permeability of steroid is improved. In addition, the heat of vaporization gives a feeling of cooling as the lower alcohol is volatilized.
- the lower alcohol include ethanol, n-propanol, and isopropanol. In the present invention, ethanol and isopropanol are preferred! /.
- the blending amount of the lower alcohol is not particularly limited, but is usually 0.1 to 70% by mass, preferably 5 to 60% by mass, and particularly preferably 10 to 50% by mass. 0.1% by mass or less In this case, sufficient cooling cannot be given to the skin, and if it exceeds 70% by mass, irritation to the skin may increase.
- the external preparation of the present invention can contain active ingredients other than steroids, antihistamines, benzoate local anesthetics, moisturizers, preservatives, stabilizers, wetting agents, and the like. It is.
- Active ingredients other than steroids, antihistamines and benzoate local anesthetics include anti-inflammatory agents such as potassium salt or ammonium salt of glycyrrhizic acid, and whitening agents such as ascorbic acid or ascorbic acid derivatives. Etc.
- humectant examples include cellulose derivatives, xanthan gum, carmellose sodium, pectin, hyaluronic acid, sodium alginate, carrageenan and the like.
- preservative examples include paraoxybenzoates, salt benzalkonium, and the like.
- Examples of the stabilizer include sodium sulfite, sodium hydrogen sulfite, dibutylhydroxytoluene, butylhydroxyl-sol, edetic acid and the like.
- wetting agent examples include polyhydric alcohols such as propylene glycol, 1,3-butylene glycol, isopropylene glycol, and polyethylene glycol.
- the external preparation of the present invention can be easily produced by a method known to those skilled in the art.
- the external preparation of the present invention can be produced by dissolving each component in an appropriate solvent and mixing them.
- the preparation for external use of the present invention can treat or alleviate symptoms of diseases or symptoms to which steroids or steroids and antihistamines are suitably applied, for example, skin disorders exhibiting various symptoms such as itching and redness. Used as a purpose. In use, an appropriate amount of the external preparation of the present invention is applied to the affected area.
- Example 1 To 45 g ethanol, add 0.025 g dexamethasone acetate and 0.5 g lidocaine And dissolved in an ethanol solution. Subsequently, 2 g of diphenhydramine hydrochloride and 0.25 g of citrate were added to 30 g of purified water and stirred to obtain an aqueous solution. Thereafter, the aqueous solution and the ethanol solution were mixed, and purified water was added and the total amount of lOOmL was obtained to obtain a solution of Example 1 (pH 6.0).
- Example 1 An ethanol solution containing no lidocaine in the preparation of Example 1 was prepared, mixed with an aqueous solution prepared in the same manner as in Example 1, and stirred. Thereafter, sodium citrate was added to adjust the pH to 6.0. Purified water was added to the solution, and the total amount of lOOmL was obtained to obtain the solution of Comparative Example 1.
- Example 2 An aqueous solution in which phosphoric acid was added instead of citrate in the preparation of Example 1 was prepared and mixed with an ethanol solution obtained in the same manner as in Example 1. Disodium hydrogen phosphate was added to the mixture to adjust the pH to 6.0. Purified water was added to the solution to make a total volume of lOOmL to obtain the liquid of Comparative Example 2.
- the residual rate of dexamethasone acetate after 2 weeks storage at 60 ° C was less than 90% in Comparative Example 1 and Comparative Example 2 Example 1 was about 95%, and the stability of dexamethasone acetate was significantly improved.
- the preparation of Example 1 was quick-drying and showed a good feeling during use.
- the residual ratio of dexamethasone acetate (content after storage at 60 ° C for 10 days Z content immediately after preparation X 100) was 96.6%, indicating that the stability of dexamethasone acetate was significantly improved.
- HPLC was used to measure the content of dexamethasone acetate.
- Lidocaine 0.5 w / v%
- Dexamethasone acetate, 1 menthol, dl-camphor and lidocaine were added to ethanol and dissolved to obtain an ethanol solution.
- diphenhydramine hydrochloride and citrate were added to purified water and stirred to obtain an aqueous solution. Thereafter, the aqueous solution and the ethanol solution were mixed to obtain a liquid for external use.
- Lidocaine 0.5 w / v%
- Lidocaine 0.5 mass 0/0
- a carboxybule polymer was added to form a gel phase.
- hydrocortisone acetate and lidocaine were dissolved in ethanol to form an ethanol phase.
- the gel phase and the ethanol phase were mixed, diisopropanolamine was added to adjust the pH to 6, and an external gel was obtained.
- Lidocaine 0.5 w / v%
- Dexamethasone acetate and lidocaine were added to isopropanol and dissolved to give an isopropanol V-solution.
- the purified water was mixed with dibuhydrochloride-in and citrate and stirred to obtain an aqueous solution. Thereafter, the aqueous solution and the isopropanol solution were mixed to obtain a liquid for external use.
- Lidocaine 0.5 w / v%
- Dexamethasone acetate and lidocaine were added to a mixed solution of propylene glycol and Macrogol 400 and heated to dissolve to obtain a polyhydric alcohol solution.
- diphenhydramine hydrochloride and citrate were added to purified water and stirred to obtain an aqueous solution. Thereafter, the aqueous solution and the polyhydric alcohol solution were mixed to obtain an external solution.
- Polysorbate 60 2. 0% by mass
- Betamethasone valerate, diisopropyl adipate, polysorbate 20, and polysorbate 60 were added to medium-chain fatty acid triglyceride and dissolved by heating to 75 ° C.
- diphenhydrochloride After dissolving doramin, lidocaine hydrochloride, propylene glycol, 1,3-butylene glycol, macrogol 400 and citrate in water and stirring this until the previous solution is uniformly emulsified, sodium citrate is added.
- the pH was adjusted to 5.5 to obtain an external cream.
- the present invention provides an external preparation containing a steroid, which is improved in the steroid stability over time and has a good feeling of use, and is useful in the pharmaceutical field and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007551158A JP5111117B2 (ja) | 2005-12-22 | 2006-12-21 | ステロイドの経時的安定性が改善された外用製剤 |
KR1020087017461A KR101121529B1 (ko) | 2005-12-22 | 2006-12-21 | 스테로이드의 경시적 안정성이 개선된 외용 제제 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-369412 | 2005-12-22 | ||
JP2005369412 | 2005-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007072923A1 true WO2007072923A1 (ja) | 2007-06-28 |
Family
ID=38188698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/325541 WO2007072923A1 (ja) | 2005-12-22 | 2006-12-21 | ステロイドの経時的安定性が改善された外用製剤 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP5111117B2 (ja) |
KR (1) | KR101121529B1 (ja) |
CN (1) | CN101340916A (ja) |
WO (1) | WO2007072923A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008150298A (ja) * | 2006-12-15 | 2008-07-03 | Toyo Capsule Kk | 溶解性を改善したジフェンヒドラミン含有医薬組成物 |
JP2013056843A (ja) * | 2011-09-08 | 2013-03-28 | Taisho Pharmaceutical Co Ltd | ステロイド性抗炎症薬含有外用剤 |
JP2013056842A (ja) * | 2011-09-08 | 2013-03-28 | Taisho Pharmaceutical Co Ltd | ステロイド性抗炎症薬含有外用剤 |
JP2013056844A (ja) * | 2011-09-08 | 2013-03-28 | Taisho Pharmaceutical Co Ltd | ステロイド性抗炎症薬含有外用剤 |
RU2486901C1 (ru) * | 2012-03-23 | 2013-07-10 | Сергей Владимирович Сирак | Поликомпонентная адгезивная мазь для лечения эрозивных поражений слизистой оболочки полости рта при обыкновенной пузырчатке |
JP2014516962A (ja) * | 2011-05-16 | 2014-07-17 | パールマン,デール,エル. | 皮膚疾患の処置のための組成物及び方法 |
JP2018108992A (ja) * | 2016-12-29 | 2018-07-12 | 小林製薬株式会社 | 乳化クリーム製剤 |
WO2022254363A1 (en) * | 2021-06-03 | 2022-12-08 | Stichting Medische Kliniek Velsen | Lidocaine or articaine for treating covid-19, autoimmune disease or cytokine storm response |
CN117338698A (zh) * | 2023-11-02 | 2024-01-05 | 中国牧工商集团有限公司 | 一种复方利多卡因凝胶剂及其制备方法 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
CA2563678A1 (en) | 2004-04-19 | 2005-11-03 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
WO2010151241A1 (en) | 2009-06-24 | 2010-12-29 | Strategic Science & Technologies, Llc | Topical composition containing naproxen |
MX337166B (es) | 2009-06-24 | 2016-02-15 | Composicion topica que contiene ibuoprofeno. | |
US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9289495B2 (en) | 2010-12-29 | 2016-03-22 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
CN105920603B (zh) | 2010-12-29 | 2022-02-11 | 战略科学与技术有限责任公司 | 勃起功能障碍和其它适应症的治疗 |
CN104127397B (zh) * | 2014-08-19 | 2016-04-27 | 董颖颖 | 一种治疗急慢性过敏性及充血性皮肤病的药物及方法 |
CN110051621A (zh) * | 2018-01-18 | 2019-07-26 | 湖北舒邦药业有限公司 | 一种复方醋酸地塞米松乳膏组合物及其制备方法 |
EA202191345A1 (ru) * | 2018-11-14 | 2021-10-08 | Авм Байотекнолоджи, Ллс | Стабильный состав глюкокортикоидов |
CN112716886B (zh) * | 2020-12-03 | 2022-07-08 | 国药集团三益药业(芜湖)有限公司 | 一种醋酸地塞米松乳膏及其制备方法 |
CN113398101B (zh) * | 2021-07-30 | 2022-06-28 | 温州医科大学附属眼视光医院 | 一种复方利多卡因凝胶贴剂 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61118315A (ja) * | 1984-11-13 | 1986-06-05 | Hokuriku Seiyaku Co Ltd | ステロイド−17−モノエステル含有クリ−ム剤 |
JPS63166837A (ja) * | 1986-12-23 | 1988-07-11 | ユージーン・ジェイ・ヴァン・スコット | 治療効果の増強された組成物 |
JPH07188027A (ja) * | 1993-12-24 | 1995-07-25 | Ss Pharmaceut Co Ltd | 安定な酪酸ヒドロコルチゾン含有クリーム剤 |
JPH10245329A (ja) * | 1997-03-05 | 1998-09-14 | Shiseido Co Ltd | 口腔用組成物 |
JP2001072603A (ja) * | 1999-09-03 | 2001-03-21 | Zeria Pharmaceut Co Ltd | 吉草酸酢酸プレドニゾロン及び塩基性局所麻酔薬を配合した外用剤 |
JP2004131472A (ja) * | 2002-08-09 | 2004-04-30 | Taisho Pharmaceut Co Ltd | 痔疾治療用軟膏 |
JP2004339213A (ja) * | 2003-04-25 | 2004-12-02 | Rohto Pharmaceut Co Ltd | 点鼻剤 |
JP2005206523A (ja) * | 2004-01-23 | 2005-08-04 | Sankyo Co Ltd | 外用鎮痒剤 |
JP2005343891A (ja) * | 2004-05-07 | 2005-12-15 | Rohto Pharmaceut Co Ltd | 皮膚外用剤 |
JP2005343890A (ja) * | 2004-05-07 | 2005-12-15 | Rohto Pharmaceut Co Ltd | 皮膚外用剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61167614A (ja) * | 1985-01-22 | 1986-07-29 | Mitsubishi Yuka Yakuhin Kk | ステロイド含有軟膏剤 |
-
2006
- 2006-12-21 WO PCT/JP2006/325541 patent/WO2007072923A1/ja active Application Filing
- 2006-12-21 JP JP2007551158A patent/JP5111117B2/ja active Active
- 2006-12-21 KR KR1020087017461A patent/KR101121529B1/ko active IP Right Grant
- 2006-12-21 CN CNA2006800477616A patent/CN101340916A/zh active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61118315A (ja) * | 1984-11-13 | 1986-06-05 | Hokuriku Seiyaku Co Ltd | ステロイド−17−モノエステル含有クリ−ム剤 |
JPS63166837A (ja) * | 1986-12-23 | 1988-07-11 | ユージーン・ジェイ・ヴァン・スコット | 治療効果の増強された組成物 |
JPH07188027A (ja) * | 1993-12-24 | 1995-07-25 | Ss Pharmaceut Co Ltd | 安定な酪酸ヒドロコルチゾン含有クリーム剤 |
JPH10245329A (ja) * | 1997-03-05 | 1998-09-14 | Shiseido Co Ltd | 口腔用組成物 |
JP2001072603A (ja) * | 1999-09-03 | 2001-03-21 | Zeria Pharmaceut Co Ltd | 吉草酸酢酸プレドニゾロン及び塩基性局所麻酔薬を配合した外用剤 |
JP2004131472A (ja) * | 2002-08-09 | 2004-04-30 | Taisho Pharmaceut Co Ltd | 痔疾治療用軟膏 |
JP2004339213A (ja) * | 2003-04-25 | 2004-12-02 | Rohto Pharmaceut Co Ltd | 点鼻剤 |
JP2005206523A (ja) * | 2004-01-23 | 2005-08-04 | Sankyo Co Ltd | 外用鎮痒剤 |
JP2005343891A (ja) * | 2004-05-07 | 2005-12-15 | Rohto Pharmaceut Co Ltd | 皮膚外用剤 |
JP2005343890A (ja) * | 2004-05-07 | 2005-12-15 | Rohto Pharmaceut Co Ltd | 皮膚外用剤 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008150298A (ja) * | 2006-12-15 | 2008-07-03 | Toyo Capsule Kk | 溶解性を改善したジフェンヒドラミン含有医薬組成物 |
JP2014516962A (ja) * | 2011-05-16 | 2014-07-17 | パールマン,デール,エル. | 皮膚疾患の処置のための組成物及び方法 |
JP2013056843A (ja) * | 2011-09-08 | 2013-03-28 | Taisho Pharmaceutical Co Ltd | ステロイド性抗炎症薬含有外用剤 |
JP2013056842A (ja) * | 2011-09-08 | 2013-03-28 | Taisho Pharmaceutical Co Ltd | ステロイド性抗炎症薬含有外用剤 |
JP2013056844A (ja) * | 2011-09-08 | 2013-03-28 | Taisho Pharmaceutical Co Ltd | ステロイド性抗炎症薬含有外用剤 |
RU2486901C1 (ru) * | 2012-03-23 | 2013-07-10 | Сергей Владимирович Сирак | Поликомпонентная адгезивная мазь для лечения эрозивных поражений слизистой оболочки полости рта при обыкновенной пузырчатке |
JP2018108992A (ja) * | 2016-12-29 | 2018-07-12 | 小林製薬株式会社 | 乳化クリーム製剤 |
JP7133309B2 (ja) | 2016-12-29 | 2022-09-08 | 小林製薬株式会社 | 乳化クリーム製剤 |
WO2022254363A1 (en) * | 2021-06-03 | 2022-12-08 | Stichting Medische Kliniek Velsen | Lidocaine or articaine for treating covid-19, autoimmune disease or cytokine storm response |
CN117338698A (zh) * | 2023-11-02 | 2024-01-05 | 中国牧工商集团有限公司 | 一种复方利多卡因凝胶剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2007072923A1 (ja) | 2009-06-04 |
CN101340916A (zh) | 2009-01-07 |
JP5111117B2 (ja) | 2012-12-26 |
KR20080080387A (ko) | 2008-09-03 |
KR101121529B1 (ko) | 2012-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5111117B2 (ja) | ステロイドの経時的安定性が改善された外用製剤 | |
EP0813413B1 (en) | Corticosteroid-containing foam | |
US11179465B2 (en) | Topical compositions comprising a corticosteroid | |
US20060045850A1 (en) | Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids | |
US20100029602A1 (en) | Low-dose mometasone formulations | |
JP2001526210A (ja) | 親油性糖質副腎皮質ステロイドおよび界面活性剤を1つだけ含有するミセルを含んでなる医薬組成物 | |
AU2009302362A1 (en) | Corticosteroid compositions for use in treating diseases of the upper and lower airway passages | |
FR2491333A1 (fr) | Compositions pharmaceutiques administrables par voie topique et contenant des steroides anti-inflammatoires | |
US20220110859A1 (en) | Composition and method for treating fungal skin conditions and inflammation | |
US20010001790A1 (en) | Topical formulations comprising skin penetration agents and the use thereof | |
EP1214055B1 (de) | Pharmazeutisches, wirkstoffhaltiges gel | |
JP2016520656A (ja) | コルチコステロイド組成物 | |
US20090233891A1 (en) | Pharmaceutical lotion comprising fluticasone propionate | |
JP3029964B2 (ja) | ステロイド類溶解剤及びステロイド類を主剤とする外用液剤 | |
JPH0231052B2 (ja) | ||
JP5909941B2 (ja) | ステロイド性抗炎症薬含有外用剤 | |
JP2005206523A (ja) | 外用鎮痒剤 | |
US20210069214A1 (en) | Topical compositions comprising a corticosteroid for the treatment of psoriasis in pediatric patients | |
BR112012005895B1 (pt) | Combinaqao e composiqao contendo um agente antimicrobiano.um glucocorticoide e um agente antifungico | |
JP2018100266A (ja) | 懸濁型外用液剤 | |
CN112386599A (zh) | 一种丁酸氢化可的松外用制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680047761.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2007551158 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087017461 Country of ref document: KR |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06843015 Country of ref document: EP Kind code of ref document: A1 |